• Model Performances
  • Microbial Underground
  • TOX Report
  • The Right Chemistry
  • Eye On The Science
  • January 2, 2013 | BY Dustin Grinnell

    The World is Getting…Larger

    In 1991 there were four states in the United States where 15-19% of the population was obese. When the CDC revised the stats in 2010, every state had an obesity rate over 20%.
    Continue Reading
  • December 17, 2012 | BY Eureka Staff

    NORD Explores the Economic Costs of Rare Disorders

    Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans.
    Continue Reading
  • December 10, 2012 | BY Timothy P. Reilly

    Untapped Drug Development Opportunities Abound

    Orphan diseases used to be a lonely place in drug development, but with recent analyses showing high profitability potential, support from disease advocacy organizations, and new therapeutic approaches, biopharmaceutical companies are beginning to embrace rare diseases, including Spinal Muscular Atrophy.
    Continue Reading
  • December 5, 2012 | BY Steven J. Bulera

    Orphan Drugs or Personalized Medicine?

    How do pharmaceutical or biotech companies afford to develop orphan drugs, knowing that their development will not be profitable?
    Continue Reading
  • November 26, 2012 | BY Nancy A. Gillett

    Abandon the Amyloid Hypothesis? Not So Fast

    After the recent failures of two Alzheimer’s drugs that target amyloid beta plaques, many have questioned the approach. But new data released in October shows promise for the amyloid hypothesis, provided plaque-targeting drugs are applied early in the disease process.
    Continue Reading
  • November 12, 2012 | BY Stephen K. Durham

    Skin Cancer Drug Effective in Mice with Alzheimer’s

    Although Alzheimer’s disease (AD) develops differently from person to person, many common symptoms exist.
    Continue Reading
  • November 5, 2012 | BY Eureka Staff

    AstraZeneca, Unraveling the Neuroscience of Alzheimer’s

    Samantha Budd, project leader for AstraZeneca’s Alzheimer’s program, discusses the challenges the biopharmaceutical industry faces with this neurodegenerative disease.
    Continue Reading
  • October 22, 2012 | BY Beth Hollister

    Improving Cancer Drugs with Animal “Avatars”

    Patient-derived xenografts, otherwise referred to as animal avatars, preserve the original characteristics of a patient’s cancer and have been shown to mimic the disease more effectively than deriving tumors from cancer cell lines.
    Continue Reading
  • October 16, 2012 | BY Eureka Staff

    Magic Bullets: The Next Evolution in Targeted Cancer Therapy

    The search for Ehrlich’s Magic Bullet took a huge leap when someone asked, “Why not antibodies?”
    Continue Reading
  • October 8, 2012 | BY Mark A. Morse

    Transgenic Mouse Models as Alternatives

    Once an experimental curiosity, pharmaceutical companies are embracing the 6-month transgenic mouse carcinogenicity study as an alternative to the 2-year mouse carcinogenicity bioassay. Here’s why.
    Continue Reading
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • Next »
Popular Tags
discovery Abstract Science safety assessment research models oncology microbial solutions toxicology neuroscience CRISPR 3Rs biologics cancer immunotherapy Alzheimer's disease
VIEW ALL
  • About Us
  • Editorial Board
  • Meeting Coverage
  • Annual Report
Legal Terms & Conditions Privacy Policy

© 2016 Charles River Laboratories International, Inc.

Home
  • Model Performances
  • Microbial Underground
  • TOX Report
  • The Right Chemistry
  • Eye On The Science
  • About Us
  • Staff Favorites
  • Tags
  • Editorial Board